AbbVie is nearing a $10.9 billion all-cash acquisition of Apogee Therapeutics, a move that would expand its footprint in inflammatory disease drugs. The reported deal is a significant strategic transaction for AbbVie and would be materially positive for Apogee if completed. The news is likely to influence both stocks and could have read-through implications for the healthcare M&A space.
AbbVie is nearing a $10.9 billion all-cash acquisition of Apogee Therapeutics, a move that would expand its footprint in inflammatory disease drugs. The reported deal is a significant strategic transaction for AbbVie and would be materially positive for Apogee if completed. The news is likely to influence both stocks and could have read-through implications for the healthcare M&A space.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately positive
Sentiment Score
0.55
Ticker Sentiment
